CCP
BIO icon

Carmel Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Carmel Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-62
Closed -$22.2K – 205
2023
Q3 		$22.2K Buy
+62
New +$23.9K 0.01% 332

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Carmel Capital Partners's BIO Position: Q4 2023 in Review

Carmel Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 62 shares — an estimated $22.2K sold.

Carmel Capital Partners first reported a position in BIO in Q3 2023 and held it in 1 quarter. The position peaked at $22.2K in Q3 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Carmel Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Carmel Capital Partners sold 62 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $22.2K.
  • Carmel Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and held it in 1 quarter.
  • Carmel Capital Partners's Bio-Rad Laboratories Class A position peaked at $22.2K in Q3 2023.
  • 483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Carmel Capital Partners's 13F filing for Q4 2023, filed 1 Feb 2024.